They trust us
Development of gene therapies using immune-shielded lentiviral vectors for treating genetic diseases in children.
C
CSR Analysis score
The organization is among the 50% most committed organizations, excluding the top 20%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: March 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Genethon
B
Research and development of gene therapy medicines for the treatment of rare diseases.
Cellectis
B
Development of cell and gene therapies using gene editing to treat cancer and other diseases. The company uses its TALEN® technology to create off-the-shelf allogeneic CAR T cells.
Transgene
A
Development of innovative immunotherapies against cancer using advanced genetic engineering and artificial intelligence technologies.
Initiatives identified among leaders
Charte éthique pour les fournisseurs et sous-traitants
“Transgene a mis en place une charte éthique pour l...” - TransgeneDéfinition d'un code de conduite éthique
“Définition d'un code de conduite éthique pour les ...” - CellectisMise en place de processus RH pour l'égalité des chances
“Transgene met en place des processus RH pour l'éga...” - Transgene36% of similar organizations communicate on CSR issues
+251 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports